https://www.live-feeds.com/feed/amgen-says-drug-combo-cuts-risk-of-death-by-58-in-patients-with-aggressive-lung-cancerContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/amgen-says-drug-combo-cuts-risk-of-death-by-58-in-patients-with-aggressive-lung-cancerhttps://www.live-feeds.com/feed/amgen-says-drug-combo-cuts-risk-of-death-by-58-in-patients-with-aggressive-lung-cancer#u161487Thu, 29 Oct 2026 09:11:31 +0000Amgen announced that its drug Imdelltra combined with AstraZeneca's Imfinzi cut the risk of death by 58 percent in patients with an aggressive form of lung cancer. Presented at the European Society for Medical Oncology presidential symposium and published in The New England Journal of Medicine, the Phase 3 DeLLphi-305 trial showed the combination extended median overall survival to 21.1 months compared to 12.7 months with Imfinzi alone. Nearly 80 percent of patients receiving the combination were alive at one year, while progression-free survival more than tripled.Why it mattersSmall cell